Hitting Multiple Immune System Targets with a Passively Targeted, Pulsed, Systemic Approach to Amplify Efficacy & Widen the Therapeutic Index

Time: 9:15 am
day: Conference Day 2


  • Taking advantage of multiple TLR/STING agonists, passive targeting and rapid clearance associated with bacteria
  • Activation of both innate and adaptive anti-tumor immunity, tumor eradication and immunological memory in pre-clinical models
  • Confirmation of a pulse-prime mechanism and update on a Phase 1 clinical trial with Decoy20